Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer

Mengying Fan | Liang Dai | Wanpu Yan | Yongbo Yang | Yao Lin | Keneng Chen

The First Department of Thoracic Surgery, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

Correspondence
Keneng Chen, The First Department of Thoracic Surgery, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Email: chenkeneng@bjmu.edu.cn

Funding information
National Key R&D Program of China, Grant/Award Number: 2017YFC0907504; the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, Grant/Award Number: ZYLD201509; the Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals, Grant/Award Number: XXT18; the National High Technology Research and Development Program of China, Grant/Award Number: 2015AA020403; the Organization Department of Beijing Municipal Party Committee, Grant/Award Number: 20180002146G259

Abstract
Background: Surgery is an important component in the treatment of esophageal cancer. For patients not eligible for R0 resection, defined as locally advanced unresectable esophageal cancer, a new approach is to transform the cancer into a resectable state by preoperative treatment. However, preoperative chemo/radiation is unsatisfactory. Therefore, the aim of this study was to assess the safety and efficacy of chemo/radiotherapy combined with a programmed cell death protein 1 (PD-1) inhibitor in the preoperative transformation of unresectable esophageal cancer.

Methods: Patients were evaluated as having unresectable, locally advanced esophageal cancer at baseline and were re-evaluated as possible R0 resection candidates after PD-1 inhibitor treatment. Patient data were derived from the prospective database of Peking University Cancer Hospital Thoracic Surgery I. Preoperative chemotherapy plus PD-1 inhibitor treatment was defined as “transformation treatment.” The objective response rate, operation rate (proportion of patients who underwent surgery), R0 rate, and treatment safety were analyzed retrospectively.

Results: A total of 36 patients were enrolled into the study, and 94.4% (34/36) completed the planned transformation treatment. The objective response rate was 71.4% (25/35), and 75% (27/36) of the patients who completed transformation treatment underwent surgery. For these surgical patients, 81.5% (22/27) obtained R0 resection, and 22.2% (6/22) had pathological complete response (pCR). During transformation treatment, 22.2% (8/36) patients had ≥grade 3 complications. There were no reoperations or perioperative deaths. After surgery, 29.6% (8/27) had ≥grade 3 complications.

Conclusions: Esophagectomy after immunotherapy is safe with acceptable complications. Compared with chemotherapy alone, chemotherapy combined with immunotherapy had a more favorable transformation effect for patients with unresectable esophageal cancer.

KEYWORDS
immunotherapy, PD-1 inhibitor treatment, unresectable esophageal cancer

INTRODUCTION
The staging of esophageal cancer determines the formulation of treatment strategy. Endoscopic treatment is generally accepted as the best treatment for patients with intramucosal cancer (T1aN0).1-4 Endoscopic treatment can eradicate the disease while protecting the organ. For locally advanced esophageal cancer (T2 or N+), the basic treatment principle is preoperative neoadjuvant treatment followed by surgery (based on current evidence), with the goal of improving long-term survival.1-4 However, in clinical practice, some patients who are evaluated as unresectable (non-R0 resection) before treatment also undergo esophagectomy after preoperative treatment. In these patients, the preoperative treatment should be regarded as transformation treatment that increases the R0 resection rate, the aim of which is to transform unresectable cancer to resectable state.
resectable status (R0). Unfortunately, the transformation rate of traditional preoperative treatment is relatively low.\textsuperscript{5–7} There are some positive data for the effect of programmed cell death protein 1 (PD-1) inhibitor treatment in advanced esophageal cancer and postoperative adjuvant treatment for locally advanced esophageal cancer.\textsuperscript{8–16} It is still uncertain whether a PD-1 inhibitor could change the paradigm of esophageal cancer treatment, in particular whether it could finally improve long-term survival. Because many clinicians are investigating preoperative immunotherapy,\textsuperscript{17–20} there is an urgent need to evaluate the safety of surgery after PD-1 inhibitor treatment. With good communication between clinicians and patients, and strict ethical supervision, it is reasonable to include immunotherapy in the preoperative setting and to perform surgery for unresectable locally advanced esophageal cancer as evaluated at baseline examination.

**METHODS**

**Patient selection**

We included patients who were treated between January 2018 and March 2021; patients were identified from the prospective database of Peking University Cancer Hospital Thoracic Surgery I. Inclusion criteria were as follows: (i) treatment of naïve patients who were pathologically confirmed as having esophageal cancer, (ii) cancers evaluated as unresectable (cT4 and/or cN3), and (iii) patients who received immunotherapy (PD-1 inhibitor). Exclusion criteria were as follows: (i) patients who were still receiving transformation treatment. The Ethics Committee of Peking University Cancer Hospital agreed exemption of informed consent for this study.

**Staging methods and follow-up**

The work-up of the patients in the prospective database included the following tests: (i) gastroscopy and biopsy, (ii) chest enhanced computed tomography (CT) and esophageal enhanced magnetic resonance imaging (MRI), (iii) positron-emission tomography (PET)-CT, and (iv) upper gastrointestinal radiography. After each cycle of transformation treatment, chest enhanced CT was performed, and, after two or four cycles of transformation treatment, gastroscopy, esophageal enhanced MRI, and PET-CT were included to evaluate the efficacy of transformation treatment. The clinical and restaging after treatment were determined twice each week at the data evaluation meeting in the Peking University Cancer Hospital Thoracic Surgery I. Patient stage was established according to the eighth TNM staging system of Union for International Cancer Control and the American Joint Committee on Cancer staging system.\textsuperscript{21}

**Transformation treatment**

The chemotherapy regimen included paclitaxel-albumin (260 mg/m\textsuperscript{2} D1) and cisplatin (75 mg/m\textsuperscript{2} D1) with a 21-day cycle. The immunotherapy regimen was a PD-1 inhibitor administered in at least two cycles. After transformation treatment, RECIST 1.1 standard was adopted for imaging evaluation. Adverse effects were evaluated according to CTCAE 4.0.

**Surgical indications**

After transformation treatment, the patients with initially unresectable esophageal cancer who obtained nonenlarged stable disease, partial, or complete response were re-evaluated as potential local (primary site and regional lymph nodes) R0 resection candidates. These candidates underwent surgery after full negotiation with the patients and their families.

**Observation indices**

Major indices: overall response rate (ORR); minor indices: surgical rate after transformation treatment, R0 resection rate, and perioperative complications. The definition and classification of perioperative complications were according to the Society of Thoracic Surgeons and the General Thoracic Surgery Database. The modified Clavien complication grading system was adopted for complication grading. Clavien 1–2 complications were defined as mild, and Clavien 3–5 were defined as severe.

**Statistical analysis**

This investigation was a nonrandomized retrospective study. SPSS 24.0 software was used for data analysis, and \( p < 0.05 \) was defined as statistically significant.

**RESULTS**

**General characteristics of patients**

Our department treated 628 esophageal cancer patients from January 2018 to March 2021. According to the inclusion and exclusion criteria, 36 patients were eventually enrolled into the study (Figure 1). Thirty-two patients (88.9%) were men, and four patients (11.1%) were women (male-to-female ratio of 8:1). The median age was 62 years (range 43–81). Table 1 shows the general characteristics of the patients and specific clinical stages. Six patients (16.7%) had cM1, five had supraclavicular lymph node metastasis, and one patient had vertebral metastasis.

**Transformation treatment and outcome**

All patients received preoperative immunotherapy, including one patient (2.8%) with immunotherapy alone,
patients received 1–7 cycles of preoperative treatment, 83.3% received 2–4 cycles of preoperative treatment, and the chemo-regimen was predominantly paclitaxel and cisplatin (94.1%). A total of 35 patients (97.2%) had restaging examinations after immunotherapy; one patient did not have a restaging examination due to severe pulmonary infection. The ORR was 71.4% (25/35), including nine clinically complete response (cCR) patients (25.7%) and 16 pCR patients (45.7%). Twenty-three patients (65.7%) had tumor downstage after treatment.

**Surgical treatment**

A total of 27 patients (75%) underwent surgery after immunotherapy, nine patients did not undergo surgery, including five with cSD/PD, three with cCR, and one patient with a grade 3 adverse effect due to immunotherapy.

Table 2 and Figure 2 summarize the general information of the 27 patients who underwent surgery. Twenty-two of the patients (81.5%) had R0 resection, one (3.7%) had R1 resection, and four patients (14.8%) had R2 resection, one of which was found to have liver metastases intraoperatively. Six patients (22.2%) had salvage surgery. The median operative time of the group was 221 min, and average blood loss was 104 ml. Fifteen patients (55.6%) had abnormal esophageal mesentery. Six patients (22.2%) had pCR as confirmed by postoperative pathological report. Twenty-three patients had endoscopic esophagectomy, two had transhiatal esophagectomy, and two patients had Sweet esophagectomy. There was no conversion to thoracotomy.
| No. | Age | Clinical stages | Stages after transformation therapy | Clinical efficacy evaluation | Surgical procedure | Surgical extent | Pathological staging | Surgical time (min) | Blood loss (ml) | Normal esophageal mesentry |
|-----|-----|----------------|-------------------------------------|-----------------------------|------------------|----------------|----------------------|------------------|---------------|-----------------------------|
| 1   | 56  | cT3N2M1        | ycT2N1M1                            | PR                          | McKeown          | R0             | ypT0N1M1             | 489              | 110           | No                          |
| 2   | 81  | cT4N2          | ycT1N0                              | CR                          | THE              | R0             | ypT0N0               | 190              | 120           | No                          |
| 3   | 53  | cT3N2M1        | ycT2N1                              | PR                          | McKeown          | R0             | ypT2N0               | 208              | 90            | Yes                         |
| 4   | 64  | cT4N2M1        | ycT1N0                              | CR                          | McKeown          | R0             | ypT0N0               | 180              | 50            | No                          |
| 5   | 62  | cT1bN3         | ycT1N3                              | SD                          | McKeown          | R0             | ypT1bN1              | 170              | 55            | No                          |
| 6   | 62  | cT4N1          | ycT2N1                              | PR                          | McKeown          | R0             | ypT2N0               | 180              | 60            | No                          |
| 7   | 81  | cT3N3          | ycT3N1                              | PR                          | McKeown          | R0             | ypT3N0               | 208              | 55            | Yes                         |
| 8   | 67  | cT4N2          | ycT4N2                              | SD                          | McKeown          | R0             | ypT4aN2              | 250              | 90            | No                          |
| 9   | 59  | cT4N3          | ycT3N2                              | PR                          | Sweet            | R0             | ypT4aN1              | 180              | 150           | No                          |
| 10  | 43  | cT4N2          | ycT3N2                              | PR                          | McKeown          | R1             | ypT2N1               | 340              | 400           | No                          |
| 11  | 70  | cT4N1          | ycT3N1                              | PR                          | McKeown          | R0             | ypT3N0               | 180              | 55            | No                          |
| 12  | 68  | cT3N3          | ycT1N0                              | CR                          | McKeown          | R0             | ypT0N0               | 150              | 90            | Yes                         |
| 13  | 71  | cT3N3          | ycT1N0                              | CR                          | McKeown          | R0             | ypT0N0               | 160              | 100           | Yes                         |
| 14  | 53  | cT4N1          | ycT2N1                              | PR                          | THE              | R0             | ypT1bN1              | 190              | 135           | Yes                         |
| 15  | 54  | cT3N3          | ycT3N2                              | PR                          | McKeown          | R0             | ypT3N1               | 160              | 105           | No                          |
| 16  | 52  | cT4N2          | ycT4N1                              | SD                          | McKeown          | R0             | ypT4aN1              | 220              | 90            | No                          |
| 17  | 45  | cT4N1          | ycT4N1                              | PD                          | Sweet            | R2             | ypT4bN2              | 380              | 300           | No                          |
| 18  | 63  | cT4N1          | ycT3N0                              | PR                          | McKeown          | R2             | ypT4bN0              | 130              | 85            | No                          |
| 19  | 61  | cT3N3          | ycT3N2                              | PR                          | McKeown          | R0             | ypT0N1               | 170              | 50            | Yes                         |
| 20  | 54  | cT3N3M1        | ycT3N3M1                            | SD                          | McKeown          | R2             | ypT4aN3M1            | 240              | 110           | No                          |
| 21  | 62  | cT3N3          | ycT1N0                              | CR                          | McKeown          | R0             | ypT0N0               | 220              | 95            | Yes                         |
| 22  | 56  | cT2N2M1        | ycT2N1                              | PR                          | McKeown          | R0             | ypT2N0               | 213              | 60            | Yes                         |
| 23  | 65  | cT2N3          | ycT2N1                              | PR                          | McKeown          | R0             | ypT1bN1              | 235              | 45            | Yes                         |
| 24  | 59  | cT3N3          | ycT3N2                              | PR                          | McKeown          | R0             | ypT3N0               | 250              | 95            | Yes                         |
| 25  | 57  | cT2N3          | ycT1N1                              | PR                          | McKeown          | R2             | ypT1bN2M1            | 240              | 105           | Yes                         |
| 26  | 65  | cT3N3          | ycT1N0                              | CR                          | McKeown          | R0             | ypT0N0               | 245              | 50            | Yes                         |
| 27  | 49  | cT4N1          | ycT3N1                              | PR                          | McKeown          | R0             | ypT3N0               | 210              | 55            | No                          |

**FIGURE 2** Waterfall chart of curative effect of transformation therapy for surgical patients.
Complications during transformation treatment

A total of 34 patients (94.4%) completed preoperative treatment; two patients did not complete the treatment plan, either because of pneumonia or upper gastrointestinal bleeding. Eight patients (22.2%) had ≥ grade 3 complications during transformation treatment, including five patients with leukocytopenia (two patients also combined with granulocytopenia), one patient with pulmonary infection, one patient with upper gastrointestinal bleeding, and one patient with hair loss. There was no death caused by the transformation treatment, and no reoperations or perioperative deaths. The postoperative complication rate was 51.9% (14/27), and ≥ grade 3 complication rate was 29.6% (8/27). Six patients incurred respiratory complications (four with pleural effusion, one with pulmonary infection, and one with respiratory insufficiency), one patient had anastomotic leakage, and one patient had anastomotic stenosis (see Table 3).

DISCUSSION

The patients assessed in this study were initially evaluated as having unresectable (non-R0) esophageal cancer, including cT4 or N3 with supraclavicular lymph nodes metastasis and staging IV esophageal cancer with M1. After preoperative treatment including a PD-1 inhibitor, the ORR was 71.4% (25/36), and 83.3% (30/36) of the patients were re-evaluated as having resectable cancers (R0). Three patients who obtained subjective clinical symptom disappearance and objective cCR refused surgical treatment. Therefore, the actual R0 resection rate was 81.5% (22/27) for patients who underwent surgery. After surgery, 22.2% (6/27) had pCR confirmed by postoperative pathology. The R0 resection rate in our study was higher than the 39.6% R0 resection rate in the study of Yokota et al., in which a DCF regimen was used.22

As to surgical safety, we suggest that it can be divided into two aspects. First, there was no perioperative death. During preoperative treatment, only one patient failed to undergo surgery due to severe pneumonia. Further, there was a complete absence of postoperative complications linked to immunotherapy. In addition, inclusion of a PD-1 inhibitor enhanced the treatment efficacy. We suggest that the addition of immunotherapy did not increase surgical difficulty or perioperative complications. However, we did observe that although intraoperative blood loss did not increase (104 ml in our group compared with 118 ml after chemotherapy alone), the surgery was more difficult. The dense fibrous scar tissue in the esophageal mesentery obscured the boundary between the “tumor” and surrounding organs and tissues during resection (55.6%), and the operation time was longer (221 min as compared with 214 min after chemotherapy alone). In addition, postoperative complications were greater than the complications of patients at earlier stages. The postoperative complication rate was 51.9% (14/27) in this study, and 29.6% (eight patients) had ≥ grade 3 complications, whereas for the entire group, the postoperative complication rate and ≥ grade 3 complication rate were 48.8% and 17.8%, respectively.23 In contrast, in the study of Yokota et al., the postoperative complication rate and ≥ grade 3 complication rate after chemotherapy alone were 76.2% (16/21) and 23.8% (5/21), respectively.22 However, it remains to be determined whether the difficulty of surgery after transformation therapy was related to immunotherapy or related mainly to the tumor itself. Our study group initially had unresectable cancers, including cT4 and multisstations of lymph nodes with extranodal invasion. In these patients, even if the tumor had shrunken after transformation treatment, there was still fibrous scarring in the esophageal mesentery. This kind of mesangial change was also common in patients with tumors of the same stage who received neoadjuvant chemo/radiotherapy.24,25

Currently, the data are promising for immunotherapy in esophageal cancer, including the second-line treatment for advanced esophageal cancer in Keynote-181,11,12 the first-line treatment for advanced esophageal cancer in Keynote-590,13 the first-line treatment for east Asian advanced esophageal squamous cell carcinoma in ATTRACTION-03,9 the adjuvant treatment for N+ patients in CheckMate-577,14 and the induction treatment for locally advanced resectable esophageal squamous cell carcinoma in PALACE-1.15 However, for this new mode of treatment, the safety of surgery is the first concern. With complete communication and strict supervision, it is a reasonable option to assess the safety of surgery after induction immunotherapy for patients with unresectable esophageal cancer.

### Table 3: Complications during transformation therapy

| Events                               | No. (%) |
|--------------------------------------|---------|
| Postoperative events of grade ≥3 (N = 27) |         |
| Pleural effusion                      | 4 (14.8%) |
| Pneumonia                            | 1 (3.7%)  |
| Respiratory insufficiency             | 1 (3.7%)  |
| Anastomotic leakage                  | 1 (3.7%)  |
| Anastomotic stenosis                 | 1 (3.7%)  |
| Events of any grade during neoadjuvant therapy (N = 36) |         |
| Leukopenia                           | 8 (22.2%) |
| Decreased neutrophil count           | 4 (11.1%) |
| Elevated transaminase                | 6 (16.7%) |
| Thyroid dysfunction                  | 3 (8.3%)  |
| Pneumonitis                          | 1 (3.7%)  |
| Esophageal hemorrhage                 | 1 (3.7%)  |
| Alopecia                             | 1 (3.7%)  |
| Events of grade ≥3 during neoadjuvant therapy (N = 36) |         |
| Leukopenia                           | 5 (13.9%) |
| Decreased neutrophil count           | 2 (5.6%)  |
| Pneumonitis                          | 1 (3.7%)  |
| Esophageal hemorrhage                 | 1 (3.7%)  |
| Alopecia                             | 1 (3.7%)  |
In clinical practice, most esophageal cancer patients are locally advanced, and they receive treatment with dismal efficacy. For the treatment principle of locally advanced resectable esophageal cancer, the current data support surgery after preoperative neoadjuvant chemoradiotherapy. However, there are some problems with preoperative chemoradiotherapy. First, preoperative chemoradiotherapy requires a high demand of treatment facilities, particularly a high demand of radiation techniques. However, not all Chinese medical centers have a radiotherapy department. For some centers, even if they have a radiotherapy department, the staff, devices, and techniques are not uniform, making radiotherapy in China hard to standardize. In addition, because the perioperative complications after chemoradiotherapy are numerous, the requirements for a management team, anesthesia, and ICU are also high. However, in China, the management team, anesthesia, ICU, and postoperative management homogenization level for esophageal cancer are also not the same. Therefore, although the data is promising for preoperative chemoradiotherapy for locally advanced esophageal cancer, the proportion of patients who receive chemoradiation is less than 10%. Conversely, neoadjuvant chemoradiation increased the pCR rate of locally advanced esophageal cancer (NEOCRTEC5010: 43.2%, CROSS: 29%); data from NECRTEC5010 and CROSS both showed that higher pCR did not mean better overall survival.26–28

For patients considered to have unresectable cancers at the time of initial diagnosis, the standard treatment was curative chemoradiotherapy. Although a small number of patients obtained long-term survival from this treatment strategy, 77.5% of patients had disease progression after treatment, and 44.4% died of tumor progression.29 At the same time, esophageal fistula caused by curative chemoradiotherapy has been of great concern in clinical practice. Yokota et al.22 conducted a phase II clinical trial of patients who had unresectable cancers at the time of initial diagnosis. The patients were treated with three cycles of transformation therapy with a DCF regimen, and were then selected for surgical resection or curative chemoradiotherapy according to the efficacy of chemotherapy. The response rate of DCF chemotherapy was 31.3%, and 37.5% (18/48) of the patients underwent the subsequent surgical treatment. One patient underwent surgical resection after chemoradiation, and the total R0 resection rate was 39.6%. There were no postoperative complications or surgery-related death.

With the introduction of immunotherapy, new theories and treatment methods should be investigated for esophageal cancer treatment strategies. These strategies should include scenarios such as preoperative treatment and postoperative treatment for patients with advanced or locally advanced resectable/unresectable disease.

Our study had some limitations. First, it was retrospective with a relatively small sample size. The aim of the study was not to measure improvement of long-term survival or R0 resection. Second, the patients had clinically unresectable cancers (cT4 or cN3), and it was not known whether the difficulty of surgery after transformation therapy was related to immunotherapy or to the tumor itself. Third, the study was an investigational observation analysis without data for long-term efficacy.

In conclusion, esophagectomy after immunotherapy is safe with acceptable complications for unresectable locally advanced esophageal cancer. Compared with chemotherapy alone, chemotherapy combined with immunotherapy might become the new treatment strategy for patients with unresectable esophageal cancer.

ACKNOWLEDGEMENTS
Funding for this work was provided by the National Key R&D Program of China (2017YFC0907504), the Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXT18), the National High Technology Research and Development Program of China (2015AA020403), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201509), and the Organization Department of Beijing Municipal Party Committee (2018000021469G259).

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest.

REFERENCES
1. Ajani JA, D’Amico TA, Bentrem DJ, D’Amico TA, Das P, Denlinger CS et al. Esophageal and esophagogastric junction cancers, version 2. 2021, NCCN clinical practice guidelines in Oncology. www.nccn.org. Accessed 05 May 2021.
2. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.
3. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2. Esophagus. 2019;16:25–43.
4. He J, Li J, Cheng Y, Fan J, Guo J, Jiang ZF, et al. Guidelines of Chinese society of clinical oncology(CSCO): Esophageal cancer. CSCO: Beijing; 2020.
5. Tsushima T, Mizusawa J, Sudo K, Honma Y, Kato K, Igaki H, et al. Risk factors for esophageal fistula associated with chemoradiotherapy for locally advanced unresectable esophageal cancer: a supplementary analysis of JCOG0303. Medicine. 2016;95:e3699.
6. Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535–41.
7. Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, et al. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78:91–9.
8. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.
9. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to one prior chemotherapy (ATTRACTION-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.
10. Shah MA, Kojima T, Hochhauser D, Enzinger P, Rainbourg J, Hollebecque A, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or
squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5:546–50.
11. Kojima T, Muro K, Francois E, Hsu CH, Moriwaki T, Kim SB, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37(Suppl 4):2.
12. Metges J, Francois E, Shah M, Adenis A, Enzinger P, Kojima T, et al. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol. 2019;30(Suppl 4):iv130.
13. Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, et al. KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15:1057–66.
14. Kelly RJ, Lockhart AC, Jonker DJ, Melichar B, Andre T, Chau I, et al. CheckMate 577: a randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastro-esophageal junction (GEJ) cancer. J Clin Oncol. 2017;35(Suppl):TPS4131.
15. Ajani JA, Kato K, Doki Y, Chau I, Xynos I, Balogh A, et al. CheckMate 648: a randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. J Clin Oncol. 2018;36:TPS193.
16. Huang J, Xu JM, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832–42.
17. Hong MH, Kim HK, Park SY, Kim DJ, Lee CG, Cho J, et al. A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2019;37(15 Suppl):4027.
18. Li C, Zhao S, Zheng Y, Han Y, Chen Y, Cheng Z, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232–41.
19. Cheng C, Yang W, Chen W, Yeung SC, Xing X, Wang X, et al. Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma. J Clin Oncol. 2021;39(3 Suppl):220.
20. Wang F, Qi Y, Meng X. Fan Q Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, open-label, phase II study. J Clin Oncol. 2021;39(3 Suppl):222.
21. Rice TW, Patil DT, Blackstone EH. 8th editionAJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30. https://doi.org/10.21037/acs.2017.03.14
22. Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. Phase II study of chemo-selection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328–34.
23. Yan WP, Zhao PL, Fu H, Lin Y, Li Z, Dai L, et al. Survival following induction chemotherapy and esophagectomy is not improved by adjuvant chemotherapy. Ann Thorac Surg. 2019 Nov;108:1505–13.
24. Tachimori Y, Kanamori N, Cemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54.
25. Markar SR, Karkhalesalingam A, Penna M, Low DE. Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol. 2014;21:922–31.
26. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36:2796–803.
27. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, Henegouwen MV, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
28. Shapiro J, van Lanschot JJ, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol. 2015;16:1090–8.
29. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definition of esophageal cancer. Thorac Cancer. 2021;12(suppl 6):7–21.
30. How to cite this article: Fan M, Dai L, Yan W, Yang Y, Lin Y, Chen K. Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer. Thorac Cancer. 2021; 1–7. https://doi.org/10.1111/1759-7714.14054

How to cite this article: Fan M, Dai L, Yan W, Yang Y, Lin Y, Chen K. Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer. Thorac Cancer. 2021; 1–7. https://doi.org/10.1111/1759-7714.14054